Detailed Mechanism Funding and Narrative

Years of mechanism: 2010 2011 2012 2013 2014 2015 2016 2017 2018

Details for Mechanism ID: 11626
Country/Region: Zambia
Year: 2015
Main Partner: Johns Hopkins University
Main Partner Program: JHPIEGO
Organizational Type: University
Funding Agency: USDOD
Total Funding: $4,119,574 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $200,000
Care: TB/HIV (HVTB) $350,000
Care: Pediatric Care and Support (PDCS) $15,536
Strategic Information (HVSI) $250,000
Health Systems Strengthening (OHSS) $300,000
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $750,000
Sexual Prevention: Other Sexual Prevention (HVOP) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $400,000
Treatment: Adult Treatment (HTXS) $1,702,242
Treatment: Pediatric Treatment (PDTX) $151,796
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
CARE_CURR_TA Age/sex: 1-4 Female 2016 100
CARE_CURR_TA Age/sex: 1-4 Male 2016 98
CARE_CURR_TA Age/sex: 10-14 Female 2016 260
CARE_CURR_TA Age/sex: 10-14 Male 2016 150
CARE_CURR_TA Age/sex: 15-19 Female 2016 315
CARE_CURR_TA Age/sex: 15-19 Male 2016 200
CARE_CURR_TA Age/sex: 20-24 Female 2016 823
CARE_CURR_TA Age/sex: 20-24 Male 2016 1,207
CARE_CURR_TA Age/sex: 25-49 Female 2016 655
CARE_CURR_TA Age/sex: 25-49 Male 2016 545
CARE_CURR_TA Age/sex: 5-9 Female 2016 300
CARE_CURR_TA Age/sex: 5-9 Male 2016 210
CARE_CURR_TA Age/sex: 50+ Female 2016 10
CARE_CURR_TA Age/sex: 50+ Male 2016 5
CARE_CURR_TA Age/sex: <1 Female 2016 52
CARE_CURR_TA Age/sex: <1 Male 2016 70
CARE_CURR_TA Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 5,000
CARE_CURR_TA Sum of Age/Sex disaggregates 2016 5,000
HTC_TST_TA Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2016 1,386
PMTCT_ARV_TA Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2016 80
PMTCT_ARV_TA Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2016 80
PMTCT_ARV_TA Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2016 10
PMTCT_ARV_TA Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2016 70
PMTCT_ARV_TA Sum of New and Current disaggregates 2016 80
PMTCT_STAT_TA By: Known positives at entry 2016 109
PMTCT_STAT_TA By: Number of new positives identified 2016 80
PMTCT_STAT_TA Number of new ANC and L&D clients 2016 924
PMTCT_STAT_TA Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2016 924
PMTCT_STAT_TA Sum of Positives Status disaggregates 2016 189
TB_SCREEN_TA Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 5,000
TX_CURR_TA Age/Sex: 1-4 Female 2016 100
TX_CURR_TA Age/Sex: 1-4 Male 2016 75
TX_CURR_TA Age/Sex: 5-14 Female 2016 14
TX_CURR_TA Age/Sex: 5-14 Male 2016 50
TX_CURR_TA Age/Sex: <1 Female 2016 1
TX_CURR_TA Age/Sex: <1 Male 2016 3
TX_CURR_TA Number of adults and children receiving antiretroviral therapy (ART) 2016 3,059
TX_CURR_TA Sum of Age/Sex disaggregations 2016 3,059
VMMC_AE_DSD Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs) 2016 21
VMMC_CIRC_DSD By Age: 10-14 2016 3,000
VMMC_CIRC_DSD By Age: 15-19 2016 2,150
VMMC_CIRC_DSD By Age: 20-24 2016 1,200
VMMC_CIRC_DSD By Age: 50+ 2016 25
VMMC_CIRC_DSD By circumcision technique: Surgical VMMC 2016 7,500
VMMC_CIRC_DSD By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery 2016 200
VMMC_CIRC_DSD By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery 2016 7,300
VMMC_CIRC_DSD By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site 2016 301
VMMC_CIRC_DSD By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program) 2016 7,127
VMMC_CIRC_DSD By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site) 2016 72
VMMC_CIRC_DSD Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period 2016 7,500
VMMC_CIRC_DSD Sum of age disaggregates 2016 6,375